FCGR1A and acute myeloid leukemia: The superiority of CD123-NKCE was confirmed on a large panels of AML cell lines (Extended Data Fig. 1a–c) coexpressing or not CD64 at the cell surface and expressing CD123 at various cell-surface densities with antibody binding capacity ranging from 580 to more than 10,000 antibody sites per cell (Extended Data Fig. 1a).